

Supplementary Table 1: Longitudinal cell counts in 150 and 1,800 pRBC infection.

Values show the median and [interquartile range]. * significance $p \le 0.05$, ** $p \le 0.005$, *** p < 0.0001 compared to day 0 (baseline).


	150 pRBC						1,800 pRBC				
	Day 0	Day 7	Day 9	Day 10	Day 11	24h post Rx	Day 0	Day 6	Day 7	Day 8	24h post Rx
Participants	6	6	6	6	6	6	21	7	21	14	14
WCC (10 ³ /mL)	7.35 [6.1-8.0]	6.75 [6.4-7.4]	6.95 [6.1-7.8]	6.9 [6.4-7.4]	6.1 [5.6-7.2]	6.2 [5.0-7.2]	5.5 [4.8-6.5]	5.8 [4.5-9.3]	5.75 [5.0-6.4]	5.0 [4.1-6.3]	5.0* [3.9-5.6]
Monocyte (10 ³ /mL)	0.3 [0.9-0.4]	0.88* [0.6-1.3]	0.48 [0.3-0.6]	0.55 [0.3-0.7]	0.68 [0.5-1.3]	0.4 [0.2-0.6]	0.46 [0.4-0.6]	0.40 [0.3-0.6]	0.45 [0.4-0.6]	0.50 [0.4-0.7]	0.50 [0.3-0.5]
Lymphocyte (10 ³ /mL)	2.1 [1.7-2.3]	2.05 [1.9-2.6]	2.15 [1.9-2.6]	2.05 [2.0-2.3]	1.85 [1.5-2.1]	1.55 [1.3-1.8]	1.98 [1.6-2.3]	2.1 [1.8-2.2]	1.8 [1.6-1.9]	1.4** [1.2-1.8]	1.2*** [0.8-1.7]
CD4⁺ T cells/ µL blood	843 [724-1112]	891 [766-1200]	926 [801-1169]	945 [844-1033]	771 [712-944]	734 [530-806]	800 [687-1100]	973 [673-1101]	798 [597-1012]	727** [517-808]	505*** [425-753]
B cells/ µL blood	247 [171-345]	246 [170-355]	292 [172-403]	278 [182-373]	254 [159-339]	158 [120-300]	263 [186-382]	274 [212-359]	277 [152-323]	251 [119-448]	167*** [86-229]
NK cells/ µL blood	218 [97-273]	195 [111-302]	235 [190-370]	215 [164-248]	144 [91-221]	165 [105-276]	114 [75-126]	131 [119-197]	92 [67-196]	47* [22-119]	27*** [16-90]




S1 Fig. CD1c⁺ mDC whole blood gating strategy. A. In the 150 pRBC cohort CD1c⁺ mDC were identified as negative for lineage markers (CD3, 14, 19, 20, 56 and 34), HLA-DR⁺ (2nd panel), CD11c⁺ (3rd panel), CD16⁻ (4th panel), back gating was also used to ensure CD11c⁺ CD16⁻ cells were not CD141⁺ (data not shown). **B.** In the 1,800 pRBC cohort CD1c⁺ mDC were identified as negative for lineage markers (CD3, 14, 19, 20, 56 and 34), HLA-DR⁺ (2nd panel), CD11c⁺ (3rd panel) and CD1c⁺ (4th panel). **C.** T cells, B cells and NK cells were gated by FSC and SSC properties (left panel), CD14 negative (middle panel) and differentiated by HLA-DR expression (right panel).



S2 Fig. Active caspase-3 staining. Percentage of CD1c⁺ mDC positive for active caspase-3 after 150 pRBC (12 participants) or 1,800 pRBC (13 participants) experimental infection. The Wilcoxon matched-paired test was used for comparison between day 0 and day 10-11 or day 7-8.



S3 Fig. Longitudinal HLA-DR expression. A. Parasitemia of participants whom longitudinal HLA-DR expression on CD1c⁺ mDC was assessed. Mean parasitemia +/- standard error is presented, 150 pRBC (white circles) or 1,800 pRBC (grey circles). **B.** Longitudinal HLA-DR MFI on CD1c⁺ mDC post 150 pRBC infection (n=12), -24h mean parasitemia 1307/mL, median parasitemia 87/ mL [IQR 1-719]. **C.** Longitudinal HLA-DR MFI on CD1c⁺ mDC post 1,800 pRBC infection (n=14; except +24h, n=7), -24h mean parasitemia 6651/mL, median parasitemia 4511 [943-12900]. Box plot show the minimum, maximum, median and interquartile range for data from all subjects. The Wilcoxon matched-paired test was used for comparison between day 0, -24h, peak and +24h.



S4 Fig. CD86 expression on CD1c⁺ mDC producing TNF to TLR ligands or pRBC. Pie charts show the proportion of TNF producing CD1c⁺ mDC which are CD86 positive (black fill) or CD86 negative (white fill) in participants administered 1,800 pRBC who had adequate CD1c⁺ mDC TNF production (\geq 30 events). CD86⁻ CD1c⁺ mDC increased in proportion on day 7, at peak parasitemia after TLR stimulation (exception pRBC), *p*=0.06. Each line of pie charts (A-E) represents one subject participating in the trial. Only A-C had adequate TNF events to be analysed for CD86 expression following pRBC stimulation. The Wilcoxon matched-paired test was used for comparison between day 0 and day 7.